Neuphoria Therapeutics (NEUP) Depreciation & Amortization (CF) (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Depreciation & Amortization (CF) of $165695.0 for Q1 2026, little changed year-over-year from $165431.0 in Q1 2025, and little changed on a QoQ basis from $165789.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $165695.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) changed 0.16% year-over-year to $165695.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $662901.0 (changed 0.01% YoY) and the FY2025 annual result came in at $662890.0, changed 0.02% from the prior year.
- Depreciation & Amortization (CF) was little changed at $165695.0 in Q1 2026 per NEUP's latest filing, from $165789.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $166121.0 in Q4 2024 and bottomed at $165431.0 in Q1 2025.
- The 4-year median for Depreciation & Amortization (CF) is $165703.0 (2024), against an average of $165741.5.
- The widest annual swing landed in 2024, when Depreciation & Amortization (CF) rose 0.26%; it then fell 0.2% in 2025.
- Tracing NEUP's Depreciation & Amortization (CF) over 4 years: stood at $165694.0 in 2023, then gained by 0.26% to $166121.0 in 2024, then decreased by 0.2% to $165789.0 in 2025, then retreated by 0.06% to $165695.0 in 2026.
- Per Business Quant, the three latest NEUP Depreciation & Amortization (CF) figures stand at $165695.0 (Q1 2026), $165789.0 (Q4 2025), and $165792.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | 165,695.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 165,695.00 |
| Mar 31, 2026 | 165,695.00 |
| Dec 31, 2025 | 165,789.00 |
| Dec 31, 2025 | 165,789.00 |
| Sep 30, 2025 | 165,792.00 |
| Sep 30, 2025 | 165,792.00 |
| Jun 30, 2025 | 165,625.00 |
| Jun 30, 2025 | 165,625.00 |
| Mar 31, 2025 | 165,431.00 |
| Mar 31, 2025 | 165,431.00 |
| Dec 31, 2024 | 166,121.00 |
| Dec 31, 2024 | 166,121.00 |
| Sep 30, 2024 | 165,713.00 |
| Sep 30, 2024 | 165,713.00 |
| Jun 30, 2024 | 165,685.00 |
| Jun 30, 2024 | 165,685.00 |
| Mar 31, 2024 | 165,703.00 |
| Mar 31, 2024 | 165,703.00 |
| Dec 31, 2023 | 165,694.00 |
| Dec 31, 2023 | 165,694.00 |
| Sep 30, 2023 | 165,909.00 |
| Sep 30, 2023 | 165,909.00 |